Literature DB >> 21813738

Metallofullerene-based nanoplatform for brain tumor brachytherapy and longitudinal imaging in a murine orthotopic xenograft model.

Michael D Shultz1, John D Wilson, Christine E Fuller, Jianyuan Zhang, Harry C Dorn, Panos P Fatouros.   

Abstract

PURPOSE: To demonstrate in an orthotopic xenograft brain tumor model that a functionalized metallofullerene (f-Gd₃N@C₈₀) can enable longitudinal tumor imaging and, when radiolabeled with lutetium 177 (¹⁷⁷Lu) and tetraazacyclododecane tetraacetic acid (DOTA) (¹⁷⁷Lu-DOTA-f-Gd₃N@C₈₀), provide an anchor to deliver effective brachytherapy.
MATERIALS AND METHODS: All experiments involving the use of mice were carried out in accordance with protocols approved by the institutional animal care and use committee. Human glioblastoma U87MG cells were implanted by using stereotactic procedures into the brains of 37 female athymic nude-Foxn1nu mice and allowed to develop into a tumor for 8 days. T1- and T2-weighted magnetic resonance (MR) imaging was performed in five mice. Biodistribution studies were performed in 12 mice at four time points over 7 days to evaluate gadolinium content. Survival studies involved 20 mice that received infusion of a nanoplatform by means of convection-enhanced delivery (CED) 8 days after tumor implantation. Mice in survival studies were divided into two groups: one comprised untreated mice that received f-Gd₃N@CC₈₀ alone and the other comprised mice treated with brachytherapy that received 1.11 MBq of ¹⁷⁷Lu-DOTA-f-Gd₃N@CC₈₀. Survival data were evaluated by using Kaplan-Meier statistical methods.
RESULTS: MR imaging showed extended tumor retention (25.6% ± 1.2 of the infused dose at 52 days, confirmed with biodistribution studies) of the f-Gd₃N@CC₈₀ nanoplatform, which enabled longitudinal imaging. Successful coupling of ¹⁷⁷Lu to the f-Gd₃N@CC₈₀ surface was achieved by using a bifunctional macrocyclic chelator. The extended tumor retention allowed for effective brachytherapy, as indicated by extended survival time (> 2.5 times that of the untreated group) and histologic signs of radiation-induced tumor damage.
CONCLUSION: The authors have developed a multimodal nanoplatform and have demonstrated longitudinal tumor imaging, prolonged intratumoral probe retention, biodistribution, and extended survival in an orthotopic xenograft brain tumor model. © RSNA, 2011.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21813738      PMCID: PMC3176419          DOI: 10.1148/radiol.11102569

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  20 in total

1.  Patient tumor EGFR and PDGFRA gene amplifications retained in an invasive intracranial xenograft model of glioblastoma multiforme.

Authors:  Caterina Giannini; Jann N Sarkaria; Atsushi Saito; Joon H Uhm; Evanthia Galanis; Brett L Carlson; Mark A Schroeder; C David James
Journal:  Neuro Oncol       Date:  2005-04       Impact factor: 12.300

Review 2.  Fullerenes: from carbon to nanomedicine.

Authors:  Pooja Chawla; Viney Chawla; Radhika Maheshwari; Shubhini A Saraf; Shailendra K Saraf
Journal:  Mini Rev Med Chem       Date:  2010-07       Impact factor: 3.862

3.  Survival of patients with newly diagnosed glioblastoma treated with radiation and temozolomide in research studies in the United States.

Authors:  Stuart A Grossman; Xiaobu Ye; Steven Piantadosi; Serena Desideri; Louis B Nabors; Myrna Rosenfeld; Joy Fisher
Journal:  Clin Cancer Res       Date:  2010-04-06       Impact factor: 12.531

4.  Recurrent high-grade glioma.

Authors:  Eudocia C Quant; Jan Drappatz; Patrick Y Wen; Andrew D Norden
Journal:  Curr Treat Options Neurol       Date:  2010-07       Impact factor: 3.598

5.  Facile preparation of a new gadofullerene-based magnetic resonance imaging contrast agent with high 1H relaxivity.

Authors:  Chunying Shu; Frank D Corwin; Jianfei Zhang; Zhijian Chen; Jonathan E Reid; Minghao Sun; Wei Xu; Jae Hyun Sim; Chunru Wang; Panos P Fatouros; Alan R Esker; Harry W Gibson; Harry C Dorn
Journal:  Bioconjug Chem       Date:  2009-06       Impact factor: 4.774

Review 6.  Biomedical applications of functionalized fullerene-based nanomaterials.

Authors:  Ranga Partha; Jodie L Conyers
Journal:  Int J Nanomedicine       Date:  2009

7.  188Re-loaded lipid nanocapsules as a promising radiopharmaceutical carrier for internal radiotherapy of malignant gliomas.

Authors:  E Allard; F Hindre; C Passirani; L Lemaire; N Lepareur; N Noiret; P Menei; J-P Benoit
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-05-09       Impact factor: 9.236

Review 8.  Gadofullerene MRI contrast agents.

Authors:  Robert D Bolskar
Journal:  Nanomedicine (Lond)       Date:  2008-04       Impact factor: 5.307

Review 9.  Nephrogenic systemic fibrosis: chronic imaging findings and review of the medical literature.

Authors:  Jeffrey P Weigle; Dale R Broome
Journal:  Skeletal Radiol       Date:  2008-03-07       Impact factor: 2.199

Review 10.  Convection-enhanced delivery of nanocarriers for the treatment of brain tumors.

Authors:  Emilie Allard; Catherine Passirani; Jean-Pierre Benoit
Journal:  Biomaterials       Date:  2009-01-24       Impact factor: 12.479

View more
  16 in total

Review 1.  Nanotechnology applications for glioblastoma.

Authors:  Edjah K Nduom; Alexandros Bouras; Milota Kaluzova; Costas G Hadjipanayis
Journal:  Neurosurg Clin N Am       Date:  2012-06-14       Impact factor: 2.509

Review 2.  Nanomedicine in the application of uveal melanoma.

Authors:  Shuo You; Jing Luo; Hans E Grossniklaus; Ma-Ling Gou; Ke Meng; Qing Zhang
Journal:  Int J Ophthalmol       Date:  2016-08-18       Impact factor: 1.779

3.  A missing link in the transformation from asymmetric to symmetric metallofullerene cages implies a top-down fullerene formation mechanism.

Authors:  Jianyuan Zhang; Faye L Bowles; Daniel W Bearden; W Keith Ray; Tim Fuhrer; Youqing Ye; Caitlyn Dixon; Kim Harich; Richard F Helm; Marilyn M Olmstead; Alan L Balch; Harry C Dorn
Journal:  Nat Chem       Date:  2013-09-15       Impact factor: 24.427

Review 4.  Strategies for improving the intratumoral distribution of liposomal drugs in cancer therapy.

Authors:  Beth Goins; William T Phillips; Ande Bao
Journal:  Expert Opin Drug Deliv       Date:  2016-04-04       Impact factor: 6.648

Review 5.  Nanotechnology to augment immunotherapy for the treatment of glioblastoma multiforme.

Authors:  Nolan Ung; Isaac Yang
Journal:  J Neurooncol       Date:  2015-06-13       Impact factor: 4.130

6.  Synthesis and evaluation of anticancer activity in cells of novel stoichiometric pegylated fullerene-doxorubicin conjugates.

Authors:  George E Magoulas; Marina Bantzi; Danai Messari; Efstathia Voulgari; Chrisostomi Gialeli; Despoina Barbouri; Athanassios Giannis; Nikos K Karamanos; Dionissios Papaioannou; Konstantinos Avgoustakis
Journal:  Pharm Res       Date:  2014-11-08       Impact factor: 4.200

Review 7.  Nanoformulations for molecular MRI.

Authors:  Chuqiao Tu; Angelique Y Louie
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2012-04-06

8.  Trimetallic Nitride Endohedral Fullerenes Carboxyl-Gd3N@C80: A New Theranostic Agent for Combating Oxidative Stress and Resolving Inflammation.

Authors:  Tinghui Li; Li Xiao; Jiezuan Yang; Mengmeng Ding; Zhiguo Zhou; Leslie LaConte; Li Jin; Harry C Dorn; Xudong Li
Journal:  ACS Appl Mater Interfaces       Date:  2017-05-19       Impact factor: 9.229

9.  Metallofullerene-nanoplatform-delivered interstitial brachytherapy improved survival in a murine model of glioblastoma multiforme.

Authors:  John D Wilson; William C Broaddus; Harry C Dorn; Panos P Fatouros; Charles E Chalfant; Michael D Shultz
Journal:  Bioconjug Chem       Date:  2012-08-21       Impact factor: 4.774

Review 10.  Image-guided interventional therapy for cancer with radiotherapeutic nanoparticles.

Authors:  William T Phillips; Ande Bao; Andrew J Brenner; Beth A Goins
Journal:  Adv Drug Deliv Rev       Date:  2014-07-09       Impact factor: 15.470

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.